CA3147100A1 - Procedes et systemes d'execution et de suivi de commande adaptatifs - Google Patents
Procedes et systemes d'execution et de suivi de commande adaptatifs Download PDFInfo
- Publication number
- CA3147100A1 CA3147100A1 CA3147100A CA3147100A CA3147100A1 CA 3147100 A1 CA3147100 A1 CA 3147100A1 CA 3147100 A CA3147100 A CA 3147100A CA 3147100 A CA3147100 A CA 3147100A CA 3147100 A1 CA3147100 A1 CA 3147100A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleotides
- order
- sample
- specimen
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 237
- 230000003044 adaptive effect Effects 0.000 title description 9
- 238000012360 testing method Methods 0.000 claims abstract description 87
- 238000012545 processing Methods 0.000 claims abstract description 86
- 238000007481 next generation sequencing Methods 0.000 claims abstract description 31
- 230000000977 initiatory effect Effects 0.000 claims abstract description 10
- 239000002773 nucleotide Substances 0.000 claims description 178
- 125000003729 nucleotide group Chemical group 0.000 claims description 178
- 206010028980 Neoplasm Diseases 0.000 claims description 163
- 108020004414 DNA Proteins 0.000 claims description 105
- 238000012163 sequencing technique Methods 0.000 claims description 98
- 230000002068 genetic effect Effects 0.000 claims description 56
- 238000013507 mapping Methods 0.000 claims description 34
- 238000007790 scraping Methods 0.000 claims description 27
- 238000011528 liquid biopsy Methods 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 208000032818 Microsatellite Instability Diseases 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 7
- 230000000869 mutational effect Effects 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 230000004075 alteration Effects 0.000 claims 4
- 230000008569 process Effects 0.000 description 145
- 239000000523 sample Substances 0.000 description 81
- 238000011282 treatment Methods 0.000 description 78
- 201000011510 cancer Diseases 0.000 description 57
- 238000003908 quality control method Methods 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 26
- 238000012512 characterization method Methods 0.000 description 24
- 238000012550 audit Methods 0.000 description 23
- 238000007726 management method Methods 0.000 description 19
- 230000007170 pathology Effects 0.000 description 19
- 238000002560 therapeutic procedure Methods 0.000 description 19
- 150000002500 ions Chemical class 0.000 description 18
- 238000012552 review Methods 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 210000002220 organoid Anatomy 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 238000009169 immunotherapy Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 238000012384 transportation and delivery Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 210000004602 germ cell Anatomy 0.000 description 8
- 238000007493 shaping process Methods 0.000 description 8
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 7
- 238000003559 RNA-seq method Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000013439 planning Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000000392 somatic effect Effects 0.000 description 7
- 239000012491 analyte Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000033607 mismatch repair Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 238000012070 whole genome sequencing analysis Methods 0.000 description 3
- 241000270650 Alytes Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000011281 clinical therapy Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000037442 genomic alteration Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000011369 optimal treatment Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000026676 system process Effects 0.000 description 2
- 101150049668 xt gene Proteins 0.000 description 2
- 108700001666 APC Genes Proteins 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 101150041972 CDKN2A gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101150069156 Cdkn2b gene Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 101100435489 Homo sapiens ARID1A gene Proteins 0.000 description 1
- 101000879619 Homo sapiens E3 ubiquitin-protein ligase CHIP Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 101150105104 Kras gene Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 101150073900 PTEN gene Proteins 0.000 description 1
- 101100424716 Patiria pectinifera TBXT gene Proteins 0.000 description 1
- 101150063858 Pik3ca gene Proteins 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101100424717 Xenopus laevis tbxt gene Proteins 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012508 change request Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 201000011045 hereditary breast ovarian cancer syndrome Diseases 0.000 description 1
- 102000053230 human STUB1 Human genes 0.000 description 1
- 101150046722 idh1 gene Proteins 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108700042657 p16 Genes Proteins 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- -1 saliva Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Primary Health Care (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne un système et un procédé de traitement d'essai génomique utilisant un moteur de gestion de commande et un ou plusieurs moteurs de traitement de commande, les moteurs de traitement de commande comprenant un moteur de réception, un moteur d'exécution et un moteur de diffusion. Le moteur de réception reçoit un état d'une commande à partir du moteur de gestion de commande. Le moteur d'exécution détermine une séquence d'étapes permettant de faire avancer l'état reçu d'une commande à un état final, désigne de manière itérative chaque étape de la séquence d'étapes telle qu'achevée avant l'initiation de l'étape suivante de la séquence d'étapes, et fait avancer l'état de la commande à un état final lorsqu'une dernière étape de la séquence d'étapes est achevée. Le moteur de diffusion diffuse l'état final de la commande au moteur de gestion de commande. Le moteur de gestion de commande amène l'un des moteurs de traitement de commande à générer un rapport de séquençage de nouvelle génération à partir de l'état final de la commande.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962873693P | 2019-07-12 | 2019-07-12 | |
| US62/873,693 | 2019-07-12 | ||
| USPCT/US2019/056713 | 2019-10-17 | ||
| PCT/US2019/056713 WO2020081795A1 (fr) | 2018-10-17 | 2019-10-17 | Systèmes et procédés de recherche et de traitement du cancer basés sur des données |
| US202016771451A | 2020-06-10 | 2020-06-10 | |
| US16/771,451 | 2020-06-10 | ||
| PCT/US2020/041862 WO2021011507A1 (fr) | 2019-07-12 | 2020-07-13 | Procédés et systèmes d'exécution et de suivi de commande adaptatifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3147100A1 true CA3147100A1 (fr) | 2021-01-21 |
Family
ID=80222056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3147100A Pending CA3147100A1 (fr) | 2019-07-12 | 2020-07-13 | Procedes et systemes d'execution et de suivi de commande adaptatifs |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3997243A4 (fr) |
| AU (1) | AU2020313915A1 (fr) |
| CA (1) | CA3147100A1 (fr) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170022558A1 (en) * | 2007-10-30 | 2017-01-26 | Complete Genomics, Inc. | Integrated system for nucleic acid sequence and analysis |
| US9133524B2 (en) * | 2010-07-01 | 2015-09-15 | The Regents Of The University Of California | Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use |
| AU2015357573B2 (en) * | 2014-12-05 | 2022-04-07 | Foundation Medicine, Inc. | Multigene analysis of tumor samples |
| TW201816645A (zh) * | 2016-09-23 | 2018-05-01 | 美商德萊福公司 | 用於生物樣本的自動化處理及分析、臨床資訊處理及臨床試驗配對之整合系統及方法 |
| CA3061128C (fr) * | 2017-01-20 | 2025-05-06 | Lifefoundry, Inc. | Systèmes et procédés de prise en charge de multiples processus automatisés |
| EP4012713B1 (fr) * | 2017-06-13 | 2025-10-29 | BostonGene Corporation | Systèmes et procédés de génération, de visualisation et de classification de profils fonctionnels moléculaires |
| CN114023403A (zh) * | 2017-11-13 | 2022-02-08 | 多发性骨髓瘤研究基金会公司 | 综合、分子、组学、免疫疗法、代谢、表观遗传学和临床数据库 |
| SG11202009696WA (en) * | 2018-04-13 | 2020-10-29 | Freenome Holdings Inc | Machine learning implementation for multi-analyte assay of biological samples |
| US20200258601A1 (en) * | 2018-10-17 | 2020-08-13 | Tempus Labs | Targeted-panel tumor mutational burden calculation systems and methods |
| CN115151974A (zh) * | 2019-12-13 | 2022-10-04 | 格里尔公司 | 使用补丁卷积神经网络的癌症分类 |
-
2020
- 2020-07-13 CA CA3147100A patent/CA3147100A1/fr active Pending
- 2020-07-13 EP EP20840833.6A patent/EP3997243A4/fr active Pending
- 2020-07-13 AU AU2020313915A patent/AU2020313915A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3997243A1 (fr) | 2022-05-18 |
| AU2020313915A1 (en) | 2022-02-24 |
| EP3997243A4 (fr) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200365232A1 (en) | Adaptive order fulfillment and tracking methods and systems | |
| US20210118559A1 (en) | Artificial intelligence assisted precision medicine enhancements to standardized laboratory diagnostic testing | |
| KR102498686B1 (ko) | 품질 제어를 위해 전자 이미지들을 분석하기 위한 시스템들 및 방법들 | |
| Kahn et al. | Transparent reporting of data quality in distributed data networks | |
| CN103460213B (zh) | 图像采集和/或图像相关参数推荐器 | |
| US10963821B2 (en) | Informatics platform for integrated clinical care | |
| CN114787934B (zh) | 有助于医疗保健成像诊断的工作流的算法编配 | |
| US12183452B2 (en) | Algorithm orchestration of workflows to facilitate healthcare imaging diagnostics | |
| US11640859B2 (en) | Data based cancer research and treatment systems and methods | |
| Spielvogel et al. | Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study | |
| Mabotuwana et al. | Automated tracking of follow-up imaging recommendations | |
| EP3534369A1 (fr) | Suivi proactif de résultats cliniques | |
| Cho et al. | Patient factor disparities in imaging follow-up rates after incidental abdominal findings | |
| CN103299339A (zh) | 诊疗支援系统 | |
| WO2022232078A1 (fr) | Systèmes et procédés de traitement d'images électroniques au moyen d'un traitement algorithmique flexible | |
| AU2019359878A1 (en) | Data based cancer research and treatment systems and methods | |
| Spaanderman et al. | AI in radiological imaging of soft-tissue and bone tumours: a systematic review evaluating against CLAIM and FUTURE-AI guidelines | |
| US20150154530A1 (en) | Method and computer program product for task management on late clinical information | |
| EP3659150A1 (fr) | Dispositif, système et procédé pour optimiser le flux de production d'acquisition d'images | |
| US11087862B2 (en) | Clinical case creation and routing automation | |
| Baskaran et al. | Predicting breast screening attendance using machine learning techniques | |
| CA3147100A1 (fr) | Procedes et systemes d'execution et de suivi de commande adaptatifs | |
| WO2021011507A1 (fr) | Procédés et systèmes d'exécution et de suivi de commande adaptatifs | |
| Hashemian et al. | Clinical deployment and validation of a radiology artificial intelligence system for COVID-19 | |
| KR20230051504A (ko) | 데이터의 자동 전송을 제공하기 위해 전자 이미지를 처리하는 시스템 및 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |